Neonatal Drug Therapy Manual


Disclaimer: Official controlled document is the CHEO and Ottawa Hospital online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
First generation (typical) antipsychotic with strong sedative effect
Original Date: 
February 2017
Revised Date: 
November 2019
  • Treatment of refractory agitation
  • IV intermittent infusion: over 20 - 30 minutes
  • SC : administer slowly (irritates skin, burn)
  • PO
  • IV/SC/PO
    • 0.1 - 0.5 mg/kg/day divided Q6-12h
Side Effects: 
  • CNS: Disruption of body temperature regulation, dizziness, drowsiness, extrapyramidal effects
  • CVS: hypotension, tachycardia, QT interval prolongation
  • Endocrine: hyperglycemia
  • GI: anticholinergic side effects such as constipation, intestinal obstruction, nausea, vomiting, xerostomia
  • Hematologic: eosinophilia, hemolytic anemia, immune thrombocytopenia, leukopenia, pancytopenia
  • Hepatic: cholestatic jaundice, hepatotoxicity
  • Renal: urinary retention
Parameters to Monitor: 
  • BP, HR
  • CBC (baseline and periodically thereafter)
  • Liver function test (baseline and periodically thereafter)
  • Glucose
Reconstitution and Stability: 

IV Intermittent Infusion:

  • Methotrimeprazine 25 mg/mL
    • Add 0.2 mL (5 mg) to 24.8 mL of 0.9% NaCl
    • Final concentration: 0.2 mg/mL


SC Bolus Injection:

  • Methotrimeprazine 25 mg/mL
    • Add 1 mL (25 mg) to 9 mL of 0.9% NaCl
    • Final concentration: 2.5 mg/mL

*** Methotrimeprazine 0.5 mg (0.2 mL) of 2.5 mg/mL solution is used for priming of CLEO device.  The CLEO should be changed every 3 to 7 days. ***


- Solutions Compatible: D5W, 0.9% NaCl

- Y-site Compatible: fentanyl, hydromorphone, morphine

- Incompatible: heparin, ranitidine


- Oral solution 0.25 mg/mL extemporaneously compounded by CHEO


- Sanne van der Zwaan, Roos J. Blankespoor, Anton M.H. Wolters and al.  Additional use of methotrimeprazine for treating refractory agitation in pediatric patients. Intensive Care Med. 2012 Jan; 38 (1): 175-176

- Holl, Christopher M, Stenekes S, Harlos Micheal S and al.  Methotrimeprazine for the management of end-of-life symptoms in infants and children. J Palliat Care 2013; 29 (3): 178-85

- Care Beyond Cure: Management of Pain and Other Symptoms, 4th Edition. A.P.E.S. 2009

- American Society of Health-System Pharmacists (ASHP). Handbook on Injectable Drugs. 19th Edition, Bethesda: ASHP 2017

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.